BeOne Medicines Ltd. — Director's Dealing 2023

Aug 2, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2023-07-31

Reporting Person: Lee Chan Henry (SVP, General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-07-31	American Depositary Shares	S	791	$216.2567	Disposed	0	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	171314	Direct

Footnotes

F1: Each American Depositary Share represents 13 Ordinary Shares.

F2: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of July 29, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.068 to $216.2962, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.